Review



phosphorylated erbb4 perbb4 y984  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc phosphorylated erbb4 perbb4 y984
    Dacomitinib reduces <t>ERBB4</t> phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.
    Phosphorylated Erbb4 Perbb4 Y984, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/phosphorylated+erbb4+perbb4+y984/Phospho-HER4%2FErbB4+(Tyr984)%2FEGFR+(Tyr978)+Antibody/pmc05916087-81-34-38
    Average 93 stars, based on 29 article reviews
    phosphorylated erbb4 perbb4 y984 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors"

    Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors

    Journal: Neoplasia (New York, N.Y.)

    doi: 10.1016/j.neo.2018.02.004

    Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.
    Figure Legend Snippet: Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

    Techniques Used: Phospho-proteomics, In Vivo, In Vitro, Staining, Standard Deviation

    Related Articles

    Immunostaining:

    Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
    Article Snippet: .. Tissue sections (5 μm) underwent microwave antigen retrieval in a citrate buffer before immunostaining with the following antibodies: Ki-67 (Leica #NCL-Ki67p, 1:5000), cleaved caspase-3 (CC3) (BD #559565, 1:500), p-EGFR Y1173 (Cell Signaling #4407, 1:250), phosphorylated ErbB4 (pErbB4) Y984 (Cell Signaling #3790, 1:50), or total ErbB4 (Santa Cruz #SC-283, 1:200). .. Sections were developed using biotinylated secondary antibodies, followed by detection with an Elite ABC kit and NovaRED peroxidase substrate, then counterstained with Gill’s hematoxylin (all from Vector Laboratories).



    Similar Products

    phosphorylated erbb4 perbb4 y984  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc phosphorylated erbb4 perbb4 y984
    Dacomitinib reduces <t>ERBB4</t> phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.
    Phosphorylated Erbb4 Perbb4 Y984, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/phosphorylated+erbb4+perbb4+y984/Phospho-HER4%2FErbB4+(Tyr984)%2FEGFR+(Tyr978)+Antibody/pmc05916087-81-34-38
    Average 93 stars, based on 1 article reviews
    phosphorylated erbb4 perbb4 y984 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors

    doi: 10.1016/j.neo.2018.02.004

    Figure Lengend Snippet: Dacomitinib reduces ERBB4 phosphorylation in vivo but antagonizes conventional medulloblastoma chemotherapeutics in vitro . (A) SMO mice harboring medulloblastomas were treated with vehicle, dacomitinib (doses indicated) or a combination of dacomitinib and cyclophosphamide (CPA, 150 mg/kg). Tumors were stained for phosphorylated or total ErbB4, stain intensity determined using ImageJ, and the ratio of phosphorylated:total ErbB4 was determined. Shown is mean ± SEM, n = 5 mice per group. Groups were compared using a Student’s t-test (* P < .05). In vitro interactions between dacomitinib and ( B ) 4-hydroperoxycyclophosphamide (4HPC), ( C ) cisplatin and ( D ) vincristine were determined using CompuSyn. Graphs show the combination index (CI) values versus factor affected (Fa) values, where values above or below the dashed line indicate antagonism or synergism, respectively. Mean CI ± standard deviation are shown. Closed circles, open squares and open triangles indicate replicate experiments.

    Article Snippet: Tissue sections (5 μm) underwent microwave antigen retrieval in a citrate buffer before immunostaining with the following antibodies: Ki-67 (Leica #NCL-Ki67p, 1:5000), cleaved caspase-3 (CC3) (BD #559565, 1:500), p-EGFR Y1173 (Cell Signaling #4407, 1:250), phosphorylated ErbB4 (pErbB4) Y984 (Cell Signaling #3790, 1:50), or total ErbB4 (Santa Cruz #SC-283, 1:200).

    Techniques: Phospho-proteomics, In Vivo, In Vitro, Staining, Standard Deviation